SpinalCyte was issued Canadian Patent No. 2,641,170, “Methods and Compositions for Repair of Cartilage using an In Vivo Bioreactor.”
The technology, which supports tissue engineering, incorporates a synthetic polymer matrix, a natural hydrogel or a synthetic hydrogel to expose fibroblasts to a mechanical strain using intermittent hydrostatic pressure or fluid shear stress. Other claims provide for growth factors such as bone morphogenetic proteins 2, 4, 6 and 7, transforming growth factor and insulin growth factor.
Source: SpinalCyte, LLC
This adds to SpinalCyte’s issued patents in Australia, Japan and the U.S.
In 2014, the company entered a final animal trial with its spinal nucleus replacement technology based on human dermal fibroblasts. Initial animal trials succeeded in regrowing the nucleus and restoring disc height by >80%.
SpinalCyte was issued Canadian Patent No. 2,641,170, “Methods and Compositions for Repair of Cartilage using an In Vivo Bioreactor."
The technology, which supports tissue engineering, incorporates a synthetic polymer matrix, a natural hydrogel or a synthetic hydrogel to expose fibroblasts to a mechanical strain using intermittent...
SpinalCyte was issued Canadian Patent No. 2,641,170, “Methods and Compositions for Repair of Cartilage using an In Vivo Bioreactor.”
The technology, which supports tissue engineering, incorporates a synthetic polymer matrix, a natural hydrogel or a synthetic hydrogel to expose fibroblasts to a mechanical strain using intermittent hydrostatic pressure or fluid shear stress. Other claims provide for growth factors such as bone morphogenetic proteins 2, 4, 6 and 7, transforming growth factor and insulin growth factor.
Source: SpinalCyte, LLC
This adds to SpinalCyte’s issued patents in Australia, Japan and the U.S.
In 2014, the company entered a final animal trial with its spinal nucleus replacement technology based on human dermal fibroblasts. Initial animal trials succeeded in regrowing the nucleus and restoring disc height by >80%.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.